LY 2886721
Alternative Names: Beta secretase inhibitor - Eli Lilly; LY-2886721; β secretase inhibitor - Eli LillyLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 18 Sep 2013 Discontinued - Phase-I for Alzheimer's disease (in volunteers) in USA (PO)
- 18 Sep 2013 Discontinued - Phase-I/II for Alzheimer's disease in USA, Italy, the Netherlands, Spain and Japan (PO)
- 13 Jun 2013 Eli Lilly voluntarily terminates the phase II portion of its phase I/II trial in Alzheimer's disease in US, Italy, Japan, Netherlands and Spain , NCT01561430)